Similar articles

• [Therapeutic depigmentation agents].

  Grosshans E, Chartier C. Grosshans E, et al. Schweiz Rundsch Med Prax. 1987 Sep 22;76(39):1077-81. Schweiz Rundsch Med Prax. 1987. PMID: 3671942 French. No abstract available.
• [Double-blind clinical study of the treatment of melasma with azelaic acid versus hydroquinone].

  Piquero Martín J, Rothe de Arocha J, Beniamini Loker D. Piquero Martín J, et al. Med Cutan Ibero Lat Am. 1988;16(6):511-4. Med Cutan Ibero Lat Am. 1988. PMID: 3073279 Clinical Trial. Spanish.
• [Irreversible toxic depigmentation. Observations following use of hydroquinonemonobenzylether-containing skin bleaching preparations].

  Heilgemeir GP, Balda BR. Heilgemeir GP, et al. MMW Munch Med Wochenschr. 1981 Jan 9;123(2):47-8. MMW Munch Med Wochenschr. 1981. PMID: 6782448 German. No abstract available.
• Pitfalls in clinical trials reveal need for well tolerated, more effective depigmenting agents.

  Saxena S, Andersen RM, Maibach HI. Saxena S, et al. J Dermatolog Treat. 2015 Oct;26(5):440-50. doi: 10.3109/09546634.2014.998609. Epub 2015 Feb 11. J Dermatolog Treat. 2015. PMID: 25669434 Review.
• Skin bleaching: highlighting the misuse of cutaneous depigmenting agents.

  Dadzie OE, Petit A. Dadzie OE, et al. J Eur Acad Dermatol Venereol. 2009 Jul;23(7):741-50. doi: 10.1111/j.1468-3083.2009.03150.x. Epub 2009 Mar 11. J Eur Acad Dermatol Venereol. 2009. PMID: 19470077 Review.